SUMMARY CXCR2 has been suggested to have both tumor-promoting and tumor-suppressive properties. Here we show that CXCR2 signaling is upregulated in human pancreatic cancer, predominantly in neutrophil/myeloidderived suppressor cells, but rarely in tumor cells. Genetic ablation or inhibition of CXCR2 abrogated metastasis, but only inhibition slowed tumorigenesis. Depletion of neutrophils/myeloid-derived suppressor cells also suppressed metastasis suggesting a key role for CXCR2 in establishing and maintaining the metastatic niche. Importantly, loss or inhibition of CXCR2 improved T cell entry, and combined inhibition of CXCR2 and PD1 in mice with established disease significantly extended survival. We show that CXCR2 signaling in the myeloid compartment can promote pancreatic tumorigenesis and is required for pancreatic cancer metastasis, making it an excellent therapeutic target.
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is an almost universally lethal malignancy and represents a significant therapeutic challenge (http://info.cancerresearchuk.org/cancerstats). Gemcitabine has been the standard of care for patients since 1997, despite offering only marginal benefit (Burris et al., 1997) . Recent improvements in survival using FOLFIRINOX and gemcitabine plus nab-paclitaxel have offered a choice to clinicians for the first time (Conroy et al., 2011; Goldstein et al., 2015) . However, the 5-year survival rate remains $6%. Surgical resection is the only potential cure; however, only 15% of patients are suitable for surgery, and most die within 2 years of surgery due to recurrence or metastatic disease. Thus, a greater understanding of how key molecular and cellular regulators of tumor progression combine to drive invasion and metastases in PDAC is required.
Pancreatic cancer develops and metastasizes as a result of the accumulation of multiple genetic and epigenetic changes. Activating mutations of the KRAS proto-oncogene occur in >90% of cases (Almoguera et al., 1988) , while inactivation of tumor Significance PDAC is predicted to become the second commonest cause of cancer death in the United States by 2020. Aggressive invasion and early metastases are characteristic of the disease, and even the few patients eligible for potentially curative resection inevitably develop recurrent or metastatic disease. Early indications suggest that immunotherapy will not work in unselected pancreatic cancer patients. Our data highlight two therapeutic opportunities for PDAC: first the use of CXCR2 inhibitors in surgically resected patients, and second the use of CXCR2 inhibition in combination with immunotherapy in surgically unresectable advanced disease. Our data also suggest that therapeutic targets that may cause senescence escape will not have deleterious effects in late-stage disease in PDAC, because tumors have already escaped this checkpoint.
suppressor genes, including CDKN2A, TP53, SMAD4, and BRCA2 accrue throughout disease development (Hruban et al., 2000) . Progression is a complex process and is reliant on interactions between the tumor and its microenvironment (Baumgart et al., 2013) . Ubiquitous to all PDAC is the dense desmoplastic stroma, consisting of immune cells, stellate cells, fibroblasts, and a dense extracellular collagenous matrix, which surrounds PDAC cells, providing vital signals for survival, tumor cell invasion, and metastasis (Olive et al., 2009 ). However, two recent studies found that targeting the stroma led to accelerated disease progression (Ozdemir et al., 2014; Rhim et al., 2014) , although both approaches provided opportunities for immunetargeting therapies. Indeed, targeting FAP + fibroblasts in pancreatic tumor-bearing mice can synergize with anti-programmed death 1 (anti-PD1) immunotherapy to cause tumor regression . Thus, there may be a complex interplay of tumor-promoting and tumor-suppressive consequences when targeting specific pathways.
The relationship between inflammation and PDAC progression is complex. Initially PDAC must overcome immune surveillance; indeed, both human and mouse pancreatic intraepithelial neoplasia (PanINs) and PDAC are characterized by the infiltration of immune suppressor cells, suggesting tumor immunity is blocked early during tumorigenesis (Clark et al., 2007) . Once immune surveillance has been bypassed, the net effect of interactions between tumor and immune cells is PDAC progression. However, certain cell types may have the capacity for tumor suppression and promotion in different contexts. For example, inflammatory signaling can promote oncogene-induced senescence (Acosta et al., 2008; Kuilman et al., 2008) . On the other hand, inflammation can drive pancreatic tumorigenesis: there is enhanced tumorigenesis in mice subjected to pancreatitis (Guerra et al., 2007) , and patients with hereditary pancreatitis have a greatly increased risk of PDAC (Lowenfels et al., 1997) . More recently, specific inflammatory signaling pathways, such as STAT3/IL-6 (Baumgart et al., 2014; Corcoran et al., 2011; Fukuda et al., 2011; Lesina et al., 2011) , NF-kB (Daniluk et al., 2012; Ling et al., 2012; Maniati et al., 2011) , and CXCR2 (Ijichi et al., 2011; Matsuo et al., 2009a) have been implicated in PDAC progression.
CXCR2 is a G-protein-coupled receptor for the human CXC chemokines CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, and CXCL8. Mouse CXCR2 has a more limited repertoire of ligands because mice lack CXCL6 and CXCL8 genes. The primary immune function of CXCR2 is the regulation of neutrophil migration, as it controls the egress of these cells from the bone marrow, and their recruitment to sites of inflammation (Cacalano et al., 1994; Eash et al., 2010) . CXCR2 also regulates the migration of myeloid-derived suppressor cells (MDSCs) (Highfill et al., 2014) . We have previously shown that CXCR2 is fundamental to the process of tumorigenesis in both colon and skin (Jamieson et al., 2012) . However, there is growing evidence that CXCR2 is also important for the metastatic process. For example, Cxcr2 deletion can reduce the invasive and metastatic potential of lung cancer cells (Saintigny et al., 2013) . In models of breast cancer, CXCR2 signaling is important for attracting Gr-1 +
CD11b
+ MDSCs to the tumor microenvironment, where they drive invasion and metastasis (Yang et al., 2008) . Moreover, CXCL1/2 secretion at metastatic sites can promote the establishment of a metastatic niche by enhancing the influx of MDSCs (Acharyya et al., 2012) . Indeed, neutrophils have recently been shown to support metastatic colonization by breast cancer cells (Wculek and Malanchi, 2015) .
There is emerging evidence for a role of neutrophils, MDSCs, and CXCR2 in pancreatic cancer. Neutrophil infiltration is observed in pancreatic tumors with the poorest prognosis (Reid et al., 2011) , while high levels of the CXCR2 ligand CXCL5 are associated with poorer survival and, by implication, metastatic disease . Recent studies have described the contribution of MDSCs to pancreatic cancer progression (Bayne et al., 2012) , and the accumulation of MDSCs in patients with advanced pancreatic cancer correlates with disease stage (Diaz-Montero et al., 2009) . Moreover, in vitro experiments and transplants in immunodeficient animals have implicated CXCR2 in the regulation of pancreatic tumor cell proliferation, invasion, and angiogenesis (Matsuo et al., 2009a (Matsuo et al., , 2009b Purohit et al., 2016; Wang et al., 2013) . CXCR2 inhibition has also been shown to disrupt interactions between tumor cells and fibroblasts to slow tumor progression in a mouse model of pancreatic cancer, although the mice used exhibit high levels of stromal deregulation and are short lived (Ijichi et al., 2011) . These tumor-promoting properties of CXCR2 may be counterbalanced by CXCR2-dependent tumor-suppressing activities. Of particular relevance to PDAC, are the elegant studies that show that CXCR2 reinforces RAS-mediated senescence in culture, and regulates the senescence-associated secretory phenotype (Acosta et al., 2008) . We therefore sought here to determine the role of CXCR2 signaling in pancreatic tumorigenesis using relevant in vivo models.
RESULTS

CXCR2
Signaling at the Tumor Border Is Associated with Poor Outcome in Human PDAC To investigate the importance of CXCR2 in human pancreatic cancer we analyzed the expression of CXCR2 and its ligands in samples from a cohort of 44 PDAC patients. RNA was prepared from targeted biopsies of tumor borders, and from the adjacent normal pancreas, and chemokine and CXCR2 expression examined. We found that genes encoding CXCR2, and two of its ligands, CXCL2 and CXCL8, were significantly upregulated compared with adjacent normal pancreas (Figure 1A) , and high CXCR2 or CXCL2 expression was associated with significantly poorer prognosis ( Figure 1B ). High CXCR2 expression was also associated with advanced T stage (p = 0.05), tumor grade (p = 0.037), and resection margin status (p = 0.015). We next examined CXCR2 protein by immunohistochemistry (IHC) on full-face sections taken from the edges of tumors adjacent to normal tissue, and found that high expression was associated with poor outcome ( Figure 1C ). Rather than being expressed in the tumor, most of the observed CXCR2 staining was within the stroma ( Figure 1D ). Further analysis of the cells present at these areas revealed high numbers of myeloperoxidase (MPO)-positive cells indicating the presence of neutrophils or their precursors (Figure 1D ). There was a significant correlation between expression of MPO and CXCR2 in the stroma at the edge of these tumors adjacent to normal regions (Spearman's rho 0.907, p = 0.01).
There were also high numbers of CD68 + macrophages, but few CD3 + T cells: these cells were, however, observed in the tissue surrounding the tumors ( Figure 1D ). Interestingly, the association of CXCR2-positive cells with prognosis appeared to depend on their location. When we examined tissue from the tumor body ( Figure S1A ), neither stromal nor tumor epithelial CXCR2 expression was associated with survival ( Figure S1B ). These data show that the effects of CXCR2 signaling, and recruitment of myeloid cells, differ depending on the site to which these cells are recruited. It is clear, however, that CXCR2 signaling and myeloid cell recruitment at the tumor border are linked to poor outcome in patients. Importantly, very few tumor cells expressed CXCR2. Figure S2B ), macrophage (F4/80, Figure S2C ) and neutrophil infiltration (MPO or S100A9, Figures S2D and  S2E ), few CD3 + T cells ) ( Figure S2F ), numerous activated a-smooth muscle actin (a-SMA)-positive stellate cells ( Figure S2G ), abundant levels of the pro-invasive protein tenascin C (Oskarsson et al., 2011 ) ( Figure S2H ), and high levels of tumor cell proliferation (marked by Ki67, Figure S2I ). It has been previously shown that KPC tumor cells express the ligands CXCL1 and CXCL2 (Stromnes et al., 2014) . When we examined the expression of CXCR2 and its ligands in tumors from KPC mice we found that, similar to human tumors, Cxcl2 and Cxcr2 were significantly upregulated in PDAC compared with normal pancreas, while there was also increased expression of Cxcl1 and Cxcl5 in a proportion of the tumors (Figure 2A ). To determine the source of ligand production we performed qPCR on RNA prepared from lasercapture micro-dissected tumor epithelium and stroma. Cxcl1, Cxcl2, Cxcl5, and Cxcr2 transcripts were quantified in these samples relative to wild-type (WT) pancreas. This demonstrated increased expression of Cxcl2 and Cxcl5 by tumor cells ( Figure 2B ). Similar to human tumors, Cxcr2 was highly expressed by stromal cells, likely neutrophils, and some tumor cells ( Figure 2B ), and this was confirmed by IHC ( Figure 2C ). Indeed, previously published work has shown that there is significant infiltration of granulocytes into KPC tumors (Clark et al., 2007), and these are likely the CXCR2-expressing cells that we observe. In addition, we found that KPC tumor cells in culture secreted substantial amounts of CXCL1 and CXCL5, and smaller amounts of CXCL2 ( Figure 2D ). Finally we analyzed expression of Cxcl1, Cxcl2, Cxcl5, and Cxcr2 by RNA sequencing (RNA-seq) of FAP + fibroblasts isolated from normal pancreas, PanIN, and PDAC from KPC mice . Expression of Cxcl1, Cxcl2, and Cxcl5 was increased in FAP + fibroblasts from PanIN and PDAC compared with WT ( Figure 2E ). CXCL1 expression by stromal fibroblasts was confirmed by co-IHC for CXCL1 and a-SMA ( Figure  2F ). CXCR2 was expressed at negligible levels in FAP + fibroblasts, and, compared with normal controls, was unchanged in PanIN and PDAC ( Figure 2E ). The expression we did observe was likely due to contamination by a very small number of neutrophils, given that we observe similar levels of MPO ( Figure 2E ). Our results show that KPC mice recapitulate the microenvironment and upregulated CXCR2 signaling seen in human PDAC, and represent an ideal model in which to investigate the role of CXCR2 signaling in pancreatic cancer.
KPC
Cxcr2 Deletion Abrogates Metastasis in KPC Mice
We generated KPC Cxcr2 À/À mice, which were born at the expected Mendelian ratios and exhibited normal pancreatic pathology. There was no difference in overall or tumor-free survival between KPC Cxcr2 À/À and KPC mice ( Figure 3A ), which initially suggested that CXCR2 was neither tumor suppressive nor tumor promoting in this system. To investigate whether inhibition of CXCR2 signaling might affect response to chemotherapy in pancreatic cancer, we treated mice with gemcitabine from 10 weeks of age. At this time mice have widespread advanced pancreatic neoplasia (Hingorani et al., 2005; Morton et al., 2010) , and are more likely to mimic non-metastatic surgically resectable disease. Using this timepoint also allowed us to monitor effects of drugs or combinations over a longer period of time. This was crucial given recent studies that have generated contrasting results depending on the timing of intervention (Olive et al., 2009; Rhim et al., 2014) . However, it is important to note that pancreata at this stage will exhibit mostly pre-invasive disease with occasional progression. Nevertheless, we did not detect any significant impact of gemcitabine treatment on survival in either KPC or KPC Cxcr2 À/À mice ( Figure 3A ).
There were no clear histological differences between tumors in KPC and KPC Cxcr2 À/À mice; however, we found that Cxcr2 deletion was sufficient to almost completely abrogate metastasis ( Figures 3B-3F ). Unsurprisingly, gemcitabine had no significant effect on metastases in the KPC model ( Figure 3B tumors, but no difference in the levels of apoptosis, as assessed by cleaved caspase 3 IHC ( Figures S3E and S3F) . We also found a decrease in picrosirius red staining indicating a reduction in collagen I expression ( Figure S3G ). Recently, we performed integrated genomic analysis of 456 human PDAC that defined four subtypes of PC that are associated with distinct histopathological characteristics and differential survival (Bailey et al., 2016) . Based on a number of key molecular characteristics, these subtypes have been named: (1) squamous; (2) pancreatic progenitor; (3) immunogenic; and (4) aberrantly differentiated endocrine exocrine (ADEX). The squamous subtype is an independent prognostic factor and is associated with poor outcomes. To further investigate the role of CXCR2 in PDAC progression we set out to assess whether loss of CXCR2 was significantly associated with a specific PDAC subtype. This analysis clearly demonstrated that CXCR2 loss is associated with an apparent switch from the poorly prognostic squamous identity commonly observed in KPC tumors, and an enrichment of gene expression that defines the pancreatic progenitor, immunogenic, and ADEX subtypes ( Figures 3I and 3J ). These data are in line with our finding that Cxcr2 deletion inhibits metastasis, and provide further evidence of a role for CXCR2 signaling in promoting aggressive pancreatic cancer.
Depletion of Ly6G+ Cells Recapitulates the Effects of
Cxcr2 Deletion Ly6G + cells, including neutrophils and MDSCs, are the most prominent source of CXCR2 in mice (Cacalano et al., 1994) . Thus, we considered whether depletion of these cells would recapitulate the phenotypes that arise as a consequence of Cxcr2 deletion. The anti-Ly6G antibody 1A8, has been routinely used to deplete Ly6G + cells, and is well-tolerated and effective long term (Jamieson et al., 2012) . KPC mice were treated from 10 weeks of age with 1A8 or 2A3 isotype control. Compared with 2A3-treated mice, and like Cxcr2 deletion, 1A8 treatment had no effect on survival ( Figure 4A ), but did result in strong suppression of metastasis ( Figure 4B ), indicating that the CXCR2-dependent recruitment of Ly6G + cells is indeed important in the establishment of secondary disease. As expected, the primary tumors of 1A8-treated mice contained fewer MPO + neutrophils than tumors from 2A3-treated mice and, importantly, 1A8 + cells were also reduced even at endpoint in both tumor and spleen ( Figures 4C-4F Although these data suggest that Ly6G + cells mediate the effects of Cxcr2 deletion, others have reported a pro-tumorigenic role for CXCR2 signaling in pancreatic tumor cells (Purohit et al., 2016; Wang et al., 2013) . To confirm that the effects of Cxcr2 deletion were not mediated by effects on autocrine tumor cell signaling we deleted Cxcr2 specifically from the pancreatic epithelium of KPC mice using a conditional floxed Cxcr2 allele (KPC Cxcr2 fl/fl ). Importantly, we did not see any effect on survival ( Figure 4G ), and we no longer observed any effects on metastasis or CD3 + T cell infiltration ( Figures 4H and 4I) , confirming that the effects of Cxcr2 deletion are not dependent on the loss of expression on the tumor cells.
CXCR2 Inhibition Reduces Metastases and Prolongs Survival in KPC Mice
Although anti-metastatic therapies may not inhibit growth of the primary tumor, they may be useful in patients where the primary tumor can be resected. Thus, we wanted to determine if See also Figure S3 .
pharmacological inhibition of CXCR2 signaling could inhibit metastasis in the KPC model. To inhibit CXCR2, we first used a short peptide CXCR2 ''pepducin'' (1/2i-pal), which inhibits CXCR2 signaling by interfering with its ability to couple to intracellular signal-transduction molecules (Jamieson et al., 2012; Kaneider et al., 2005) . Control mice received a scrambled pepducin. Other groups of KPC mice received gemcitabine alone, or gemcitabine along with the CXCR2 pepducin. All treatments were started when the mice were 10 weeks old. CXCR2 pepducin treatment resulted in a significant increase in survival compared with controls and appeared to reduce metastasis ( Figures 5A and 5B). Gemcitabine alone had no effect on survival or the development of metastasis, but when CXCR2 pepducin and gemcitabine were combined, survival was significantly extended and we were unable to detect any metastases in these animals ( Figures 5A and 5B). We did not see significant changes in neutrophil, macrophage, or CD3 infiltration in pepducintreated mice ( Figures 5C, 5D , and S4A-S4C), although the number of infiltrating neutrophils was significantly higher in mice treated with the combination of CXCR2 pepducin and gemcitabine ( Figure S4A ), which may be due in part to necrosis within these tumors. Indeed, tenascin C, the expression of which is induced by hypoxia (Lal et al., 2001) , was upregulated in pepducin-treated tumors ( Figures 5C, 5D , and S4D). There was no significant change in either tumor cell proliferation or apoptosis ( Figures S4E and S4F ), but again we saw a decrease in picrosirius red staining indicating a reduction in collagen I ( Figure S4G ).
CXCR2 Inhibition Results in Failure to Set up a Metastatic Niche
Given the profound effect that inhibiting CXCR2 signaling has on metastasis in our model, we sought to examine potential mechanisms for this phenomenon, particularly in distant metastatic sites. MDSCs are immature bone marrow cells typified by the expression of CD11b, Gr1, and Ly6G/Ly6C (Youn and Gabrilovich, 2010) . They have been shown to play a role in establishing the metastatic niche in different metastatic tumor models (Acharyya et al., 2012; Yan et al., 2010) . Therefore, we investigated the levels of these, and other immune cells, in the pre-metastatic livers of KPC mice ( Figure S4H ), in KPC liver metastases (Figure S4I) , in the livers of KPC mice treated with pepducin and gemcitabine from 10 weeks old ( Figure S4J ), and in liver metastases from KPC mice treated with CXCR2 pepducin and gemcitabine when symptomatic ( Figure S4K ). We included this latter group because of the lack of metastases in KPC Cxcr2 À/À mice and mice with CXCR2 inhibited from 10 weeks. We found that there were a substantial number of F4/80 + macrophages, NIMP1 + neutrophils, and cells staining positively with the MDSC marker, S100A9, in the pre-metastatic liver (Figure S4H) , and in established liver metastases where there were also CXCR2-expressing cells ( Figure S4I ). CXCR2 inhibition with pepducin considerably decreased the number of myeloid cells in the livers of KPC mice ( Figure S4J ) and, even in mice with late-stage tumors, reduced the number of neutrophils and S100A9 + cells infiltrating liver metastases, although had no effect on monocyte/macrophage recruitment ( Figure S4K ). Interestingly, the number of CD3 + T cells infiltrating these metastases was increased compared with untreated mice, in line with our observations in primary tumors. The changes we observe in primary tumors and metastases following CXCR2 inhibition suggest that the migration of myeloid lineage cells to the tumor microenvironment is impaired when CXCR2 signaling is suppressed. This reduction in chemotaxis may also result in a failure of myeloid cells to migrate to the liver and establish a niche for tumor cells. These findings suggest a key role for CXCR2 signaling and immune cell migration in metastatic progression in this model.
Clinically Relevant Targeting of CXCR2 Reduces Metastases and Prolongs Survival in KPC Mice
The finding that CXCR2 inhibition but not constitutive knockout could slow tumorigenesis suggested that CXCR2 might play opposing roles in early and late tumorigenesis. Loss during initiation might allow pre-neoplastic PanIN lesions to progress beyond senescence, while loss at late stages might inhibit the growth and metastatic potential of PDAC. Thus, we wanted to further test the therapeutic effects of CXCR2 inhibition at a later stage of neoplasia, using a clinically relevant CXCR2 inhibitor. Therefore, we tested the effects of AZ13381758, a small-molecule inhibitor of CXCR2 (referred to as CXCR2 SM) that is related to AZD5069 (Nicholls et al., 2015) . AZ13381758 is a potent inhibitor of both murine and human CXCR2 ( Figures S5A-S5F , Table  S1 ), the efficacy of which was confirmed by full blood-count analysis showing increased circulating neutrophils due to their inability to home ( Figure 6A ). Similar to CXCR2 pepducin, treatment with CXCR2 SM alone from 10 weeks of age prolonged the survival of KPC mice, and was most effective in combination with gemcitabine ( Figure 6B ). In addition, mice treated with CXCR2 SM were significantly protected from metastasis ( Figure 6C ). We did not observe significant changes in the number of intra-tumoral neutrophils or macrophages ( Figures 6D, 6F , S5G, and S5H), similar to pepducin treatment; however, we did observe an increase in infiltrating T cells ( Figures 6D, 6F , and S5I), similar to the results seen in KPC Cxcr2 À/À mice. We also saw a reduction of tenascin C ( Figures   6D, 6F , and S5J), a reduction in the number of proliferative cells ( Figure S5K ), no change in apoptosis ( Figure S5L ), and a reduction in stromal collagen ( Figure S5M ) in CXCR2 SM-treated tumors. Thus, like Cxcr2 deletion or Ly6G + cell depletion, pharmacological inhibitors of CXCR2 can reduce the metastatic spread of pancreatic tumors in KPC mice and may provide a survival advantage over control animals. More significantly, the combination of CXCR2 inhibition and gemcitabine treatment extends the life span of KPC mice by 50-70 days and substantially suppresses metastasis.
CXCR2 Inhibition Substantially Enhances Sensitivity to Anti-PD1 Immunotherapy
There is a growing awareness that immunosuppression by infiltrating immune cells plays an important role in the resistance of tumors to endogenous anti-tumor immune responses as well as therapeutic interventions. Pancreatic cancer cells themselves actively contribute to immune suppression through production of cytokines (Beatty et al., 2011) , so that although a systemic anti-tumor immune response is elicited, it is ineffective (Dodson et al., 2011) . The efficacy of therapy in PDAC would likely be improved by overcoming this immune suppression. Indeed, immunotherapy aimed at harnessing endogenous anti-tumor immunity has shown promise in multiple tumor types (Sharma and Allison, 2015) . Given that Cxcr2 deletion or inhibition increased the number of CD3 + T cells in pancreatic tumors in KPC mice, we wanted to know if CXCR2 inhibitors could enhance sensitivity to therapies aimed at de-repressing T cells. We chose to use anti-PD1 antibodies, which block T cell suppression by preventing interactions between PD1 and its ligands (Barber et al., 2006; Fife et al., 2009 ), but which have previously been found to be ineffective as a single agent in this model . In this experiment, treatment was only started once the KPC mice had developed palpable pancreatic tumors. One group of mice then received CXCR2 SM for 2 weeks to increase T cell infiltration into the tumor. Control mice received either vehicle alone or gemcitabine alone. After this initial priming phase, animals in the CXCR2 SM and vehicle groups received anti-PD1 antibody while continuing on the CXCR2 SM or vehicle treatments. Unsurprisingly, given that they are carrying late-stage tumors, few vehicle-treated animals survived long enough (2 weeks) to allow commencement of PD1 treatment ( Figure 7A ). Remarkably, however, even in these late-stage tumors, treatment with CXCR2 SM and anti-PD1 significantly extended survival beyond that of the mice treated with vehicle plus anti-PD1, with two mice living 100 days beyond the start of treatment before succumbing to pancreatic tumors ( Figure 7A ).
When tumors from mice at endpoint were examined by IHC for Ki67 and cleaved caspase 3 (CC3) we observed a reduction in proliferation following CXCR2 SM + anti-PD1 treatment ( Figures  7B and 7C ), but no change in apoptosis ( Figures 7D and 7E ), Figure 7F ). We were able to show by both IHC ( Figure 7G ) and fluorescenceactivated cell sorting (FACS) analysis ( Figure 7H ) that the number of both CD4 + and CD8 + T cells was increased in CXCR2 SM-treated mice and, importantly, the number of inhibitory regulatory T cells was actually reduced ( Figure 7H ). Interestingly, in vehicle-treated mice a substantial proportion of both CD4 + and CD8 + T cells exhibited an effector memory phenotype (CD62L À CD44 + ). In contrast, in CXCR2 SM-treated mice, this population was less abundant, and a greater proportion of the CD4 + and CD8 + T cells expressed a naive T cell phenotype (CD62L + CD44 -) perhaps allowing for increased intratumoral T cell priming ( Figure 7I) .
Collectively, our data show that in KPC mice, Cxcr2 deficiency, Ly6G + cell depletion, or pharmacological inhibition of CXCR2 suppresses metastasis in PDAC, and that CXCR2 inhibitors enhance response to chemotherapeutics and immunotherapy to prolong survival. These results suggest that CXCR2 targeting might have therapeutic efficacy in the pre-metastatic setting, and may provide an opportunity for immunotherapy in pancreatic cancer.
DISCUSSION
The outcome for patients suffering from PDAC remains dismal (Siegel et al., 2015) , and it is clear that improvements in pancreatic cancer treatment are required. Here, we show that CXCR2 signaling in the myeloid compartment is tumor promoting and required for pancreatic cancer metastasis, and in the notoriously therapy-resistant KPC model of pancreatic cancer we highlight therapeutic opportunities: Not only does inhibition of CXCR2 prevent metastasis; it also augments the efficacy of immune checkpoint inhibitors by allowing T cell infiltration. Indeed, when we compare our mouse tumors with human tumors, we find that Cxcr2 deletion is associated with a switch away from the poorly prognostic squamous identity (Bailey et al., 2016) . Our data support other studies linking inflammation and metastasis (Colotta et al., 2009; Kim et al., 2009) and suggest that inflammatory signaling molecules may be excellent targets in the neoadjuvant treatment of pancreatic cancer. A number of key inflammatory pathways, including IL-6/STAT3, NF-kB, and COX2 pathways, have already been shown to be key in the process of PDAC progression and metastasis (Corcoran et al., 2011; Daniluk et al., 2012; Fukuda et al., 2011; Lesina et al., 2011; Ling et al., 2012) . Indeed, patients with significant tumor-associated inflammation have a poor prognosis following surgery (Jamieson et al., 2005) .
It has been suggested that pancreatic tumors metastasize prior to the development of a detectable mass in the pancreas (Haeno et al., 2012; Rhim et al., 2012) . However, we found that whether CXCR2 signaling was targeted by genetic or pharmacological means, alone, or in combination with chemotherapy, metastasis was significantly inhibited. The ameliorated recruitment of immature myeloid cells to metastatic sites suggests that CXCR2 functions at multiple stages of the metastatic process, hence the striking effect on metastases seen following genetic knockout. In addition, given that CXCR2 inhibition can restrict pancreatitis, targeting CXCR2 signaling in cancer may have additional benefit in terms of ameliorating symptoms (Steele et al., 2015) .
Predicting the outcome of targeting stromal elements within PDAC has been difficult. Combination of anti-stromal agents and chemotherapy represents a promising approach to therapy in this disease, with encouraging findings in studies targeting the extracellular matrix glycosaminoglycan or hyaluronic acid (Jacobetz et al., 2013) . On the other hand, recent studies targeting tumor-associated fibroblasts and hedgehog signaling at different stages of tumorigenesis produced differing results, with accelerated tumorigenesis if treatment was early and improved survival for late-stage treatment (Olive et al., 2009; Ozdemir et al., 2014; Rhim et al., 2014) . The results we present here suggest that CXCR2 has stage-and also cell-type-specific roles in PDAC cancer. During early carcinogenesis, CXCR2 can reinforce senescence in epithelial cells (Acosta et al., 2008) ; however, once the senescence pathway is abrogated, MDSC/neutrophil CXCR2 drives tumor progression and metastasis. We propose this as the reason that Cxcr2 deletion had no overall effect on survival of KPC mice. These findings are consistent with the expression of CXCR2 in human cancer, which is expressed in Figure S5 and Table S1 .
PanINs and more rarely in epithelial tumor cells, but is highly expressed in neutrophils/MDSCs at tumor fronts.
We do find that a subset of human tumors show high epithelial CXCR2 expression; however, it is unclear what role CXCR2 is playing in those tumors. Many studies have shown that CXCR2 expression on cancer cells can drive proliferation, invasion, and migration (Matsuo et al., 2009a (Matsuo et al., , 2009b Purohit et al., 2016; Wang et al., 2013) . However, our data showing that epithelial cell-specific Cxcr2 loss has no effect on tumor-free survival or metastasis suggests that the effects we observe in the case of Cxcr2 deletion or inhibition are not mediated by tumor cell expression. Together, these findings highlight an intriguing idea, namely, that tumor cells develop a requirement for autocrine CXCR2 signaling once explanted, as a result of loss of the paracrine signaling that exists in vivo. This hypothesis would further underscore the importance of CXCR2 signaling in pancreatic cancer.
Given that most of the mutations that accompany KRAS mutation in PDAC have been shown to abrogate growth arrest/ senescence, for example CDKN2A, TP53, and TGFb pathwaytargeting mutations, and the fact that at the time of presentation tumors are highly proliferative and not senescent, concerns over treatment of patients with PDAC with CXCR2 inhibitors are negated. Any remaining concerns are alleviated given the good efficacy we have seen with combination with gemcitabine or anti-PD1. This clearly differentiates CXCR2 inhibition from other stromal targeting agents such as hedgehog inhibitors.
Among the stromal changes we observed following CXCR2 inhibition, one of the most striking was enhanced T cell infiltration. This enhanced T cell infiltration may be responsible for the increased efficacy of gemcitabine, given that enhanced T cell accumulation in KPC tumors can induce stromal remodeling (Stromnes et al., 2015) , which in turn can increase the efficacy of gemcitabine (Olive et al., 2009; Provenzano et al., 2012) . The infiltration of T cells also rendered tumors sensitive to immunotherapy with PD1-blocking antibody. There are a number of possible mechanisms by which CXCR2 inhibition enables T cell infiltration. For example, we observed a decrease in monocyte/macrophage tumor infiltration in treated mice, and a role for macrophages in the exclusion of T cells from pancreatic tumors has been described (Beatty et al., 2015) .
Immunotherapy to reactivate anti-tumor immunity has delivered promising results in several tumor types (Sharma and Allison, 2015) , but not, as yet, in pancreatic cancer. Dose scheduling will be important in future clinical trials, given that CXCR2 targeting may be most effective when used to prime the tumor microenvironment. Indeed, the anti-metastatic effect we observe was uncovered when treating mice at an early time point with mostly pre-invasive disease and, as such, may not truly reflect the clinical situation. Nevertheless, our results Cytokine Array on Medium Conditioned by KPC Cells Murine pancreatic cancer cell lines have been described previously (Morton et al., 2010) . AAM-CYT-G2000-4 Ray Biotech slides (Holzel Diagnostics) were used according to the manufacturer's protocol. Laser scanning using the Cy3 channel was used for detection of protein expression.
In Vivo Treatment Experiments
For drug treatments, mice were randomly assigned to cohorts. Treatments used were: CXCR2 pepducin (X1/2pal-i3, Genscript) or scrambled pepducin at 2.5 mg/kg by subcutaneous injection daily; gemcitabine (LC Laboratories) at 100 mg/kg by intraperitoneal (i.p.) injection twice weekly; CXCR2 SM (AstraZeneca) at 100 mg/kg per os (p.o.) twice daily; vehicle p.o. twice daily; anti-PD1 (Biolegend) or isotype control at 10 mg/kg by i.p. injection twice weekly; 1A8 antibody or 2A3 isotype control (BioXcell) at 10 mg/kg by i.p. injection thrice weekly. Efficacy testing of CXCR2 SM is described in Supplemental Experimental Procedures.
Statistical Analysis
Kaplan-Meier survival analysis was performed using log rank tests. Assessment of differences in counts between different mice was performed using non-parametric Mann-Whitney U tests. For all boxplots in the paper, boxes depict the middle 50% of the records and the line indicates the median. Whiskers show the highest and lowest values that are no greater than 1.5 times the interquartile (IQ) range, and asterisks show outliers (cases with values between 1.5 and 3 times the IQ range). Chi-square tests were used to assess the statistical differences in metastasis rate between categorical groups. Spearman's rho correlation coefficient method was used to assess correlation. ANOVA test was used for analysis of qPCR data.
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